Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Risk Factors for Severe Outcomes in Patients With Systemic Vasculitis and COVID‐19: A Binational, Registry‐Based Cohort Study
Matthew A. Rutherford, Jennifer Scott, Maira Karabayas, et al.
Arthritis & Rheumatology (2021) Vol. 73, Iss. 9, pp. 1713-1719
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression
Maria Prendecki, Candice Clarke, Helena Edwards, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. 1322-1329
Open Access | Times Cited: 229
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
Levente Zsichla, Viktor Müller
Viruses (2023) Vol. 15, Iss. 1, pp. 175-175
Open Access | Times Cited: 71
Rheumatological complications of Covid 19
Hannah Zacharias, Shirish Dubey, Gouri Koduri, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 9, pp. 102883-102883
Open Access | Times Cited: 104
Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions
Marco Krasselt, Ulf Wagner, Phuong Nguyen, et al.
Lara D. Veeken (2022) Vol. 61, Iss. SI2, pp. SI180-SI188
Open Access | Times Cited: 49
Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study
Sebastian E. Sattui, Richard Conway, Michael Putman, et al.
The Lancet Rheumatology (2021) Vol. 3, Iss. 12, pp. e855-e864
Open Access | Times Cited: 47
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS
Kate Stevens, Eleni Frangou, Jae Il Shin, et al.
Nephrology Dialysis Transplantation (2022) Vol. 37, Iss. 8, pp. 1400-1410
Open Access | Times Cited: 29
The COVID-19 pandemic and ANCA-associated vasculitis – reports from the EUVAS meeting and EUVAS education forum
Andreas Kronbichler, Duvuru Geetha, Rona Smith, et al.
Autoimmunity Reviews (2021) Vol. 20, Iss. 12, pp. 102986-102986
Open Access | Times Cited: 38
Immunogenicity, Effectiveness, and Safety of COVID-19 Vaccines in Rheumatic Patients: An Updated Systematic Review and Meta-Analysis
Kuo‐Tung Tang, Bo‐Chueh Hsu, Der‐Yuan Chen
Biomedicines (2022) Vol. 10, Iss. 4, pp. 834-834
Open Access | Times Cited: 28
Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses
Benazir Saleem, Rebecca L. Ross, Lesley-Anne Bissell, et al.
RMD Open (2022) Vol. 8, Iss. 1, pp. e002050-e002050
Open Access | Times Cited: 23
Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
Beatriz Sánchez‐Álamo, Jan Henrik Schirmer, Bernhard Hellmich, et al.
RMD Open (2023) Vol. 9, Iss. 2, pp. e003083-e003083
Open Access | Times Cited: 10
Immunologic Response and Effects of COVID-19 Vaccines in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Ki Hyun Lee, Hyunsue Do, Jun Yong Choi, et al.
Yonsei Medical Journal (2025) Vol. 66, Iss. 5, pp. 259-259
Open Access
The mortality and acute complications of large vessel vasculitis patients hospitalized with COVID-19 in the US: a nationwide inpatient sample analysis (2020)
Nattanicha Chaisrimaneepan, Chanokporn Puchongmart, Pannathorn Nakaphan, et al.
Rheumatology International (2025) Vol. 45, Iss. 3
Closed Access
Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination
Christof Specker, Peer Aries, J. Braun, et al.
Zeitschrift für Rheumatologie (2021) Vol. 80, Iss. S2, pp. 33-48
Open Access | Times Cited: 21
Overview of infections as an etiologic factor and complication in patients with vasculitides
Panagiotis Theofilis, Aikaterini Vordoni, Maria Koukoulaki, et al.
Rheumatology International (2022) Vol. 42, Iss. 5, pp. 759-770
Open Access | Times Cited: 16
Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients
Tommaso Schioppo, Lorenza Maria Argolini, Savino Sciascia, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 5, pp. 1928-1935
Open Access | Times Cited: 19
Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli et al
Caoilfhionn M Connolly, Darya Koenig, Srekar N. Ravi, et al.
Annals of the Rheumatic Diseases (2021) Vol. 80, Iss. 10, pp. e164-e164
Closed Access | Times Cited: 19
COVID-19 infection, admission and death among people with rare autoimmune rheumatic disease in England: results from the RECORDER project
Megan Rutter, Peter Lanyon, Matthew J. Grainge, et al.
Lara D. Veeken (2021) Vol. 61, Iss. 8, pp. 3161-3171
Open Access | Times Cited: 18
Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess
Frederick Vogel, Martín Reincke
Reviews in Endocrine and Metabolic Disorders (2021) Vol. 23, Iss. 2, pp. 233-250
Open Access | Times Cited: 17
COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
Annette Bruchfeld, Andreas Kronbichler, Federico Alberici, et al.
Nephrology Dialysis Transplantation (2021) Vol. 36, Iss. 9, pp. 1758-1760
Open Access | Times Cited: 16
COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study
Marco Krasselt, Christoph Baerwald, Olga Seifert
Vaccines (2022) Vol. 10, Iss. 2, pp. 253-253
Open Access | Times Cited: 8
COVID-19 infection, admission and death and the impact of corticosteroids among people with rare autoimmune rheumatic disease during the second wave of COVID-19 in England: results from the RECORDER Project
Megan Rutter, Peter Lanyon, Matthew J. Grainge, et al.
Lara D. Veeken (2023) Vol. 62, Iss. 12, pp. 3828-3837
Open Access | Times Cited: 4
Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung
Christof Specker, Peer Aries, J. Braun, et al.
Zeitschrift für Rheumatologie (2021) Vol. 80, Iss. 6, pp. 570-587
Open Access | Times Cited: 8
Single-cell RNA sequencing to decipher the immunogenicity of ChAdOx1 nCoV-19/AZD1222 and mRNA-1273 vaccines in patients with autoimmune rheumatic diseases
Yen–Ju Chen, Po‐Liang Cheng, Wen‐Nan Huang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 6
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients
Mary J. Kasten, Brian D. Lahr, Anusha Parisapogu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
CVAPPS: A Cross-Sectional Study of SARS-CoV-2 Vaccine Acceptance, Perceptions, and Post-Vaccination Side Effects among Rheumatic Disease Patients in Kuwait
Fatemah Baroun, Anwar Albasri, Fatemah Abutiban, et al.
Vaccines (2023) Vol. 11, Iss. 3, pp. 666-666
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top